| Overview |
| bs-13928R-FITC |
| CHPF Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| May have slight cross reactivity with CHPF2 due to sequence similarity of the following amino acids "RTRYI" within the immunogen |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Pig |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CHPF |
| 51-150/775 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 79586 |
| Q8IZ52 |
| Cell membrane |
| Chondroitin sulfate synthase 2, Chondroitin-polymerizing factor, Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II,
N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase II,
N-acetylgalactosaminyltransferase 2 |
| Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Isoform 2 may facilitate PARK2 transport into the mitochondria. In collaboration with PARK2, isoform 2 may enhance cell viability and protect cells from oxidative stress. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz